LNTH Stock: Lantheus Holdings, Inc. Stock Price, Analysis & Insights
Get live lnth stock price $55.15, comprehensive Lantheus Holdings, Inc. stock analysis, charts, news, and expert forecast. Real-time lnth stock data and investment insights.
Company Overview
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Company Information
- CEO
- Brian A. Markison
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 808
Contact Information
- Website
- https://www.lantheus.com
- Address
- 331 Treble Cove Road
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 3.75B market capitalization
- Trading Volume: 498.43K shares traded today
- Price Range: 52-week range of $47.25 - $118.21
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Lantheus Holdings, Inc.
Lantheus Holdings, Inc. (LNTH) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. With a current market capitalization of 3.75B, the company represents a significant player in its market. The stock is currently trading at $55.15 with a positivedaily change of 2.48%.
The company's 808 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 14.67, beta of 0.15, and 52-week price range from $47.25 to $118.21when evaluating investment opportunities.
Why Invest in Lantheus Holdings, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under Brian A. Markison
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.